RAD · ASX

Radiopharm Theranostics Limited (ASX:RAD)

AU$0.024

 0.003 (14.286%)
ASX:Live
20/12/2024 04:10:10 PM
HALO Ords HALO Growth HALO Consensus Value GROWTH AUS Big Candle +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RAD Overview

RAD Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Weak

Growth

Earnings

Very Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About RAD

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053

Description

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

RAD Price Chart

Key Stats

Market Cap

AU$50.14M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.1

Trade Value (12mth)

AU$29,709.00

1 week

-27.59%

1 month

-19.23%

YTD

-71.23%

1 year

-70%

All time high

0.45

Key Fundamentals

EPS 3 yr Growth

6794.40%

EBITDA Margin

%

Operating Cashflow

-$23m

Free Cash Flow Return

-63.40%

ROIC

-132.30%

Interest Coverage

-55.00

Quick Ratio

1.30

Other Data

Shares on Issue (Fully Dilluted)

446m

HALO Sector

Healthcare

Next Company Report Date

25-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RAD Announcements

Latest Announcements

Date Announcements

20 December 24

RAD 202 receives approval to start Phase 1 therapeutic trial

×

RAD 202 receives approval to start Phase 1 therapeutic trial

19 December 24

Response to ASX Aware Letter

×

Response to ASX Aware Letter

19 December 24

Application for quotation of securities - RAD

×

Application for quotation of securities - RAD

19 December 24

Notice Under Section 708A

×

Notice Under Section 708A

18 December 24

Application for quotation of securities - RAD

×

Application for quotation of securities - RAD

18 December 24

Notification regarding unquoted securities - RAD

×

Notification regarding unquoted securities - RAD

18 December 24

Change of Director's Interest Notices x7

×

Change of Director's Interest Notices x7

18 December 24

Notification of cessation of securities - RAD

×

Notification of cessation of securities - RAD

10 December 24

Completion of preclinical data package for RAD 402

×

Completion of preclinical data package for RAD 402

10 December 24

Change of Director's Interest Notice PH

×

Change of Director's Interest Notice PH

02 December 24

Notification of cessation of securities - RAD

×

Notification of cessation of securities - RAD

02 December 24

Constitution

×

Constitution

27 November 24

Radiopharm achieves Nasdaq listing of ADS

×

Radiopharm achieves Nasdaq listing of ADS

25 November 24

Presentation to Annual General Meeting

×

Presentation to Annual General Meeting

25 November 24

Results of Meeting

×

Results of Meeting

19 November 24

Approval received to expand RAD204 Phase 1 trial

×

Approval received to expand RAD204 Phase 1 trial

18 November 24

RAD 301 shows strong imaging potential in pancreatic cancer

×

RAD 301 shows strong imaging potential in pancreatic cancer

29 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

25 October 24

Notice of Annual General Meeting

×

Notice of Annual General Meeting

23 October 24

RAD 202 data presented at 2024 EANM Annual Meeting

×

RAD 202 data presented at 2024 EANM Annual Meeting

23 October 24

Change of Director's Interest Notice - IT

×

Change of Director's Interest Notice - IT

21 October 24

BAMF Health to manufacture & dose for RAD101 Phase 2b trial

×

BAMF Health to manufacture & dose for RAD101 Phase 2b trial

16 October 24

RAD partners with AtomVie to develop B7H3 trial doses

×

RAD partners with AtomVie to develop B7H3 trial doses

03 October 24

Significant progress with B7-H3 targeting radio-antibody

×

Significant progress with B7-H3 targeting radio-antibody

03 October 24

Initial Director's Interest Notice - ND

×

Initial Director's Interest Notice - ND

RAD Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.11 -0.11 -0.12 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.11 -0.11 -0.12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5,938.9 1.7 -16.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.08 -0.07 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.07 -0.06 Lock Lock Lock
     Growth % Lock Lock Lock Lock -9,552.5 -73.9 13.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -25.9 -72.4 -156.5 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.23 0.12 0.06 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 -0.04 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 5,577.7 -260.1 -15.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 280 324 386 Lock Lock Lock
Basic m Lock Lock Lock Lock 280 324 386 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A 2.3 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 17 37 36 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -3 -3 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -0.8 100.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -1,027.6 0.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 1,128 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -17 -37 -35 Lock Lock Lock
     Growth % Lock Lock Lock Lock -3,395.3 -118.3 4.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -12,654.3 -11,810.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 3 3 3 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -20 -40 -38 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4,010.4 -102.2 4.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -13,781.8 -12,855.2 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -30 -40 -49 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -6 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -30 -35 -48 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6,169.7 -13.8 -38.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -11,838.6 -16,024.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -10 -23 -23 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 28 2 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -28 -2 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 65 9 30 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -10 -23 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30,011.1 -134.6 1.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -79.5 -76.8 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 27 12 19 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 83 75 72 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -27 -12 -19 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 20 29 45 Lock Lock Lock
Equity $m Lock Lock Lock Lock 63 44 28 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 63 44 28 Lock Lock Lock
     Growth % Lock Lock Lock Lock 50,590.1 -29.5 -36.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -36.5 -46.2 -66.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -48.3 -78.0 -170.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -63.4 -74.2 -105.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -96.8 -64.5 -132.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -31.5 -43.2 -63.4 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -1.8 -429.7 -55.0 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.6 0.3 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -42.8 -26.4 -66.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.5 1.2 1.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.5 1.2 1.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 99.0 71.8 81.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -125.7 -175.4 -130.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 1,011.3 2,150.4 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 -13,849.6 -16,424.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 -54.0 -68.2 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -36.5 -46.2 -66.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.7 2.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -48.3 -78.0 -170.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -48.3 -78.0 -170.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 2,824.3 3,327.2 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 2,824.3 3,327.2 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 76.8 229.5 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -76.8 2,594.7 3,327.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAD Shortsell

Frequently Asked Questions

The current share price of Radiopharm Theranostics Limited (RAD:ASX) is AU$0.024.
The 52-week high share price for Radiopharm Theranostics Limited (RAD:ASX) is AU$0.10.
The 52-week low share price for Radiopharm Theranostics Limited (RAD:ASX)? is AU$0.02.
Radiopharm Theranostics Limited (RAD:ASX) does not pay a dividend.
Radiopharm Theranostics Limited (RAD:ASX) does not pay a dividend.
Radiopharm Theranostics Limited (RAD:ASX) has a franking level of 0.0%.
Radiopharm Theranostics Limited (RAD:ASX) is classified in the Healthcare.
The current P/E ratio for Radiopharm Theranostics Limited (RAD:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.